Edition:
United Kingdom

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

0.47USD
18 Jan 2019
Change (% chg)

$-0.12 (-19.82%)
Prev Close
$0.59
Open
$0.50
Day's High
$0.54
Day's Low
$0.47
Volume
459,327
Avg. Vol
58,444
52-wk High
$7.68
52-wk Low
$0.24

Latest Key Developments (Source: Significant Developments)

Sunesis Announces Pricing Of $20 Mln Offering Of Securities
Friday, 18 Jan 2019 

Jan 17 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS ANNOUNCES PRICING OF $20 MILLION OFFERING OF SECURITIES.ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERINGS OF 23 MILLION SHARES OF ITS COMMON STOCK AT $0.50.PRICING OF UNDERWRITTEN PUBLIC OFFERINGS OF 17,000 SHARES OF ITS NON-VOTING SERIES E CONVERTIBLE PREFERRED STOCK AT $500.SUNESIS EXPECTS TO RECEIVE COMBINED GROSS PROCEEDS OF APPROXIMATELY $20 MILLION FROM THESE OFFERINGS.  Full Article

Sunesis Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Preferred Stock
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PREFERRED STOCK.  Full Article

Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017.SUNESIS PHARMACEUTICALS INC - SWISHER TO REMAIN WITH SUNESIS AS A STRATEGIC ADVISOR.SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018.  Full Article

Sunesis Pharmaceuticals Appoints William Quinn As CFO
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT.SUNESIS PHARMACEUTICALS INC - ‍WILLIAM QUINN MOST RECENTLY SERVING AS CEO AND CO-FOUNDER OF PRIVATE CANCER IMMUNOTHERAPY COMPANY BULLET BIOTECHNOLOGY​.  Full Article

Sunesis Pharmaceuticals Inc Q3 loss per share ‍$0.43​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights.Sunesis Pharmaceuticals Inc qtrly loss per share ‍$0.43​.Sunesis Pharmaceuticals Inc- ‍pro-forma Sept 30, 2017 cash, cash equivalents and marketable securities of $37.1 million is expected to fund co into 2019​.  Full Article

Sunesis announces pricing of $20 million offering of securities
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc ::Sunesis announces pricing of $20 million offering of securities.Sunesis Pharmaceuticals Inc - pricing of underwritten public offerings of 7.5 million shares and accompanying warrants to purchase 3.8 million shares​.Sunesis Pharmaceuticals- ‍also priced 2,500 shares of non-voting series D convertible preferred stock, accompanying warrants to purchase 1.3 million shares​.  Full Article

Sunesis Pharmaceuticals announces proposed public offering of common stock, preferred stock and warrants
Tuesday, 24 Oct 2017 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis announces proposed public offering of common stock, preferred stock and warrants.Sunesis Pharmaceuticals Inc - ‍anticipates using net proceeds from proposed offerings to fund development of sns-062, additional kinase inhibitor programs​.  Full Article